LEXEO THERAPEUTICS INC. - COMMON STOCK

4,3300

18-февраля-25 15:00:22

15 мин. задержка

Акции

-0,1700

-3,78%

Сегодняшний диапазон

4,2100 - 4,7199

ISIN

N/A

Источник

NASDAQ

Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

07 янв 2025 06:30:00 Источник Nasdaq GlobeNewswire
Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer

19 дек 2024 06:00:00 Источник Nasdaq GlobeNewswire
Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results

13 ноя 2024 06:30:00 Источник Nasdaq GlobeNewswire
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference

30 окт 2024 05:14:00 Источник Nasdaq GlobeNewswire
Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference

22 окт 2024 06:30:00 Источник Nasdaq GlobeNewswire
Lexeo Therapeutics to Participate in Upcoming Investor Conferences

05 сен 2024 06:30:00 Источник Nasdaq GlobeNewswire
Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights

12 авг 2024 06:00:00 Источник Nasdaq GlobeNewswire
Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

15 июл 2024 05:00:00 Источник Nasdaq GlobeNewswire
Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024

11 июл 2024 07:00:00 Источник Nasdaq GlobeNewswire
Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors

08 июл 2024 06:00:00 Источник Nasdaq GlobeNewswire
Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights

09 май 2024 06:00:00 Источник Nasdaq GlobeNewswire
Lexeo Therapeutics to Participate in Upcoming Investor Conferences

07 май 2024 06:30:00 Источник Nasdaq GlobeNewswire
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

22 апр 2024 06:30:00 Источник Nasdaq GlobeNewswire
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy

16 апр 2024 06:30:00 Источник Nasdaq GlobeNewswire
Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing

13 мар 2024 15:22:39 Источник Nasdaq GlobeNewswire
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

11 мар 2024 06:42:39 Источник Nasdaq GlobeNewswire
Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing

11 мар 2024 06:30:00 Источник Nasdaq GlobeNewswire
Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments

05 фев 2024 06:00:00 Источник Nasdaq GlobeNewswire
Lexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 янв 2024 06:00:00 Источник Nasdaq GlobeNewswire
Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)

18 дек 2023 06:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.